SMN-C3
Catalog No: 20344
CAS Number: 1449597-34-5
Purity: ≧98.0%
SMN-C3 is an orally active SMN2 splicing modulator and has the potential to treat spinal muscular atrophy (SMA). SMN-C3 is in phase I clinical trials co-developed by Roche and PTC Therapeutics for the treatment of spinal muscular atrophy.
For research use only. We do not sell to patients.
Chemical Information
| Name | SMN-C3 |
|---|---|
| Iupac Chemical Name | 2-(4,6-Dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethylpiperidin-4-yl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one |
| Synonyms | SMN-C3 ; SMN C3 ; SMNC3 |
| Molecular Formula | C24H28N6O |
| Molecular Weight | 416.52 |
| Smile | O=C1C=C(C2=NN3C(C(C)=NC(C)=C3)=C2)N=C4N1C=C(C5CCN(CC)CC5)C=C4C |
| InChiKey | ZACWYYKZMLGOTG-UHFFFAOYSA-N |
| InChi | InChI=1S/C24H28N6O/c1-5-28-8-6-18(7-9-28)19-10-15(2)24-26-20(12-23(31)29(24)14-19)21-11-22-17(4)25-16(3)13-30(22)27-21/h10-14,18H,5-9H2,1-4H3 |
| CAS Number | 1449597-34-5 |
| Related CAS | 1449597-34-5 |
Ordering Information
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Light-yellow solid |
|---|---|
| Purity | ≧98.0% |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Solubility | Soluble in DMSO |
| Handling | Refer to MSDS operation |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| HS Code | 2934200090 |
Coming soon.
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
Not available
Chemical Structure
